You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 22, 2024

KETALAR Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


Which patents cover Ketalar, and when can generic versions of Ketalar launch?

Ketalar is a drug marketed by Endo Operations and is included in one NDA.

The generic ingredient in KETALAR is ketamine hydrochloride. There are eight drug master file entries for this compound. Twelve suppliers are listed for this compound. Additional details are available on the ketamine hydrochloride profile page.

DrugPatentWatch® Litigation and Generic Entry Outlook for Ketalar

A generic version of KETALAR was approved as ketamine hydrochloride by HIKMA on March 22nd, 1996.

  Subscribe

AI Research Assistant
Questions you can ask:
  • What is the 5 year forecast for KETALAR?
  • What are the global sales for KETALAR?
  • What is Average Wholesale Price for KETALAR?
Summary for KETALAR
Drug patent expirations by year for KETALAR
Drug Prices for KETALAR

See drug prices for KETALAR

Recent Clinical Trials for KETALAR

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Brian Anderson, MDPhase 4
Jay FournierPhase 1/Phase 2
Stanford UniversityPhase 2

See all KETALAR clinical trials

Pharmacology for KETALAR
Drug ClassGeneral Anesthetic
Physiological EffectGeneral Anesthesia

US Patents and Regulatory Information for KETALAR

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Endo Operations KETALAR ketamine hydrochloride INJECTABLE;INJECTION 016812-001 Approved Prior to Jan 1, 1982 AP RX Yes Yes ⤷  Subscribe ⤷  Subscribe ⤷  Subscribe
Endo Operations KETALAR ketamine hydrochloride INJECTABLE;INJECTION 016812-002 Approved Prior to Jan 1, 1982 AP RX Yes No ⤷  Subscribe ⤷  Subscribe ⤷  Subscribe
Endo Operations KETALAR ketamine hydrochloride INJECTABLE;INJECTION 016812-003 Approved Prior to Jan 1, 1982 AP RX Yes No ⤷  Subscribe ⤷  Subscribe ⤷  Subscribe
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.